Genmab — August 2018
-
God morgen.
-
Nej det kan man kikke forstille sig. Det tager typisk 2-5 mdr at forberede ansøgningen. Hvor de 2 høre til sjældenhederne. Der er plus 100.000 siders data når man indsender sådan en ansøgning
-
Ved ikke rigtigt, det der er med til at gøre Dara til sådan en cashcow er f.eks. at det ikke helbreder patienterne, det gør dem kronisk syge. Havde det helbredt patienterne villle vi ikke kunne malke dem for penge i årevis. Så der er ikke en sådan simpel sammenhæng.
-
Her er det nye studie med ADCT-301/Cami-T (various solid tumors). Tror ikke det var været vist her på sitet før. https://clinicaltrials.gov/ct2/show/NCT03621982?term=Daratumumab+OR+Ofatumumab+OR+Tisotumab+OR+Camidanlumab+OR+HuMax-AXL-ADC&lupd_s=08%2F08%2F2018&lupd_e=08%2F12%2F2018&rank=4
-
Winkel er glad for Immatics-aftalen: So we think that combining the expertise and the knowledge of both of these companies can really move us into unlocking solid cancers for very effective T-cell mediated tumor cell killing. This is not being shown now with any other approach, neither CAR T, neither other CD3 bispecifics up to this moment.
-
Mere: I actually looked at this for a very long time. I can tell you that we have compared at least six other companies' technologies with what Immatics was doing, and we reached the conclusion that is this is basically the absolute front-runner in this new area.
-
-
Har lige kopieret nogle tal fra en skribent fra et andet forum.
-
Ser tallene ikke ret høje ud?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind